Biotech Stock Mailbag: Discovery Labs
I asked Chrisian Itin, Micromet's CEO, about any changes to the company's relationship with AstraZeneca during a call Thursday morning. He wouldn't answer the question, stating only that as of now, the arrangement with AstraZeneca remains as it was.
It's hard to say what this all means. If blinatumomab were a great drug in the making, why did AstraZeneca relinquish North American rights last March?
Perhaps AstraZeneca's pipeline priorities changed and it could no longer devote resources to the drug. That's entirely possible, but then why would AstraZeneca also decide to accept just $6 million to further give up an option to reacquire the rights to the drug if it did turn out to be a big moneymaker sometime in the future?
If Micromet does buy out AstraZeneca completely, the company will own unencumbered worldwide rights to blinatumomab, which is being developed right now in two hematologic cancer indications. The company also has other drugs in earlier stages of development, some partnerned with other companies, and a platform to generate new antibodies.Perhaps Wednesday night's money raise and the complete divorce from AstraZeneca is a precursor to a newer and more lucrative partnership or even an acquisition. Or, perhaps not.
A correction and further comment: When I filmed this week's video on Biocryst Pharmaceuticals (BCRX), I inadvertently described the company's flu drug as a vaccine. Peramivir is an antiviral used to treat patients infected with the flu virus; it is not a vaccine used to protect people from getting infected in the first place.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV